The story of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial introduction generated substantial returns, the lapse of its exclusive rights opened the avenue to cheaper https://haimaiiiw003427.buyoutblog.com/41847670/sildenafil-and-the-pharmaceutical-industry-a-volatile-investment